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Abstract 
The general goal of the proposed diploma work was preparation and 
characterization of crosslinked hyaluronan microfibres, which would be stable 
in aqueous environment with proper mechanical properties. 
The fibres prepared by the wet spinning technique, were crosslinked with solution 
containing crosslinking reagent 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide 
or two crosslinking reagents, 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide and 
N-hydroxysuccinimide, leading to amidation and formation of ester bonds. 
Characterization of prepared samples is the main goal of experimental part of the 
thesis. The swelling characteristics were carried out to determine the stability of fibres 
in three different solutions (with pH 7.4, 3 and 11). For determination of thermal 
stability was used thermogravimetrical analysis, and for determination of esterification 
and amidation was used infrared spectroscopy with Fourier transformation. Mechanical 
properties of fibres were studied by stress-strain tester. Additionally, the rheological 
properties were investigated, as well as the microstructure and surface of fibres 
by scanning electron microscopy. 
The fibres before chemical crosslinking had lower stability in all three types 
of solutions; the thermal stability was also lower, than the stability of crosslinked fibres. 
For not chemically modified fibres with crosslinking reagent, only one type of peak 
for esterification occurred. The infrared spectra of chemically crosslinked fibres showed 
the presence of two esterification peaks, which was the result of the effectiveness of the 
crosslinkig reagent. Amidation was also stronger for crosslinked fibres, especially 
for fibres crosslinked long time and in the solution with higher concentration 
of crosslinking reagent. Due to the heterogeneity of fibres, mechanical properties did 
not show evidence of any dependence on the crosslinking. The rheological study 
showed that the viscosity of fibre dissolved in water is less dependent on the shear rate 
than the powder of sodium hyaluronan dissolved in water. 
Despite more different methods of characterization of fibres which were used 
in this work, there are still many options for better characterization and closer 
understanding of this biopolymeric material. 
 
 
 
Keywords 
biopolymers, hyaluronic acid, microfibers, crosslinking 
 
 
 
 4 
Abstrakt 
Všeobecne, cieľom tejto diplomovej práce bola príprava a charakterizácia 
sieťovaných hyaluronových mikrovláken, ktoré by boli stabilné vo vodnom prostredí 
s vhodnými mechanickými vlastnosťami. 
Vlákna pripravené technikou zvlákňovania z roztoku boli sieťované pomocou 
roztoku so sieťovacím činidlom 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimidom 
alebo roztoku s dvoma sieťovacími činidlami 1-Ethyl-3-(3-dimethylaminopropyl) 
carbodiimidom a N-hydroxysuccinimidom, vedúcim k amidácii a tvorbe esterových 
väzieb. 
Charakterizácia pripravených vzoriek je hlavným cieľom experimentálnej časti 
práce. Charakteristiky botnání boli vykonané na určenie stability vláken v troch rôznych 
roztokoch (s pH 7.4, 3 a 11). Na určenie termickej stability bola využitá 
termogravimetrická analýza a na stanovenie esterifikácie a amidácie bola použitá 
infračervená spektroskopia s Fourierovou transformáciou. Mechanické vlastnosti vláken 
boli študované pomocou testovania závislosti stress-strain. Ďalej boli testované 
reologické vlastnosti ako aj mikroštruktúra a povrch vláken pomocou skenovacieho 
elektrónového mikroskopu.  
Vlákna pred chemickým sieťovaním vykazovali nižšiu stabilitu vo všetkých troch 
roztokoch, termálna stabilita bola taktiež nižšia ako stabilita zosieťovaných vláken.  
Pre vlákna chemicky nemodifikované so sieťujúcim činidlom, sa objavil iba jeden 
typ píku pre esterifikáciu. Infračervené spektrum chemicky zosieťovaných vláken 
ukázalo prítomnosť dvoch píkov pre esterifikáciu, čo je prejavom efektivity 
sieťovacieho činidla. Amidácia bola tiež výraznejšia pri zosieťovaných vláknach, 
špeciálne pre vlákna sieťované dlhú dobu a v roztoku s vyššou koncentráciou 
sieťujúceho činidla. Kvôli nerovnomerným vláknam, mechanické vlastnosti 
nevykazovali žiadnu závislosť na sieťovaní. Štúdium reológie ukázalo, že viskozita 
vlákna rozpusteného vo vode je menej závislá na šmykovej rýchlosti ako prášok 
hyaluronanu sodného rozpusteného vo vode.  
Napriek mnohým rôznym metódam charakterizácie vláken, ktoré boli použité 
v tejto práci, je stále veľa možností pre lepšiu charakterizáciu a bližšie pochopenie tohto 
biopolymérneho materiálu. 
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1 INTRODUCTION 
Inspired in the nature, in the formation of fibres in plants, man-made fibres are 
important form of materials. [1] In history, artificial fibrous structures in the form 
of textiles were used as clothing and decorations. In the past century, fibre-based 
techniques have been widely used in numerous engineering applications such as 
filtration, composite fabrication, energy systems, and micro-fluidics. Recently, some 
of the fibre-based techniques have been applied for tissue engineering for preparation 
of scaffolds. [2] Fibrous scaffolds normally have large surface area and volume, 
homogeneous fibre size and a wide range of pore distribution. [3] 
In tissue engineering and medicine, biopolymers are widely used due to their 
similarities with the extracellular matrix, high chemical versatility, typically good 
biological performance and inherent cellular interaction, and the cell or enzyme-
controlled degradability. [4] These materials allow supplement, or replace the functions 
of living tissues of the human body. [5]. One of these naturally occurring biopolymers 
with important biological functions is hyaluronic acid. This high molecular weight 
polysaccharide is widely used in many medical fields, from different types of surgeries 
to wound healing. In the tissue engineering, mentioned ability of wound healing is the 
desirable property of hyaluronic acid, where the degradation products of hyaluronic acid 
are able to modulate wound healing. [6][7] 
Combining the advantages of fibres with the properties of hyaluronic acid, wound 
dressings can be a proper result. Wound dressings are used to encourage wound healing 
and create better healing conditions. Hyaluronic acid can also be used as a carrier for 
other wound healing agents. [8] 
The main aim of the work is to crosslink hyaluronan fibers by using 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) with/without N-hydroxysuccinimide (NHS) 
for the first time. The second aim of study is characterization of prepared fibres 
and their comparison.  
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2 THEORETICAL PART 
2.1 Fibres 
Fibres can be referred to as oriented polymers and in general, fibres are at least 
100 times longer than they are wide. [9][10] They are an important form of polymer 
materials; they are of great practical importance in creating domestic objects (clothing, 
carpets, etc.) or technical agents (medical articles, insulating materials, etc.), but can 
also be found in animal and plant world (skeletal structures, connective tissues, skin 
and protective membranes, etc.). [1] 
The properties of fibres are function of many factors, primarily the chemical 
composition of the polymer and the physical state of the polymer in the fibre, i.e., its 
structure. [12] A number of properties of man-made polymer fibres are associated 
with natural fibre formation. These shared properties of natural and man-made polymer 
fibres include mechanical (strength and deformational) structural (relationship between 
crystalline, interphase, and amorphous state) characteristics, the nonequilibrium 
physical state and relaxation phenomena, and the effect of the chemical structure of the 
polymer material on the stability of the fibres in time. [1] 
Despite the difference in the properties of different polymer fibres, all the fibres 
have common structural properties that determine their mechanical, thermal, and other 
properties. [9] Two basic types of structures occur in fibres: 
Macrostructure - structural regions are comparable to the transverse dimensions 
of a fibre. It includes segments with different density, porosity, orientation of the 
polymer chains, crystallinity, etc. The size of the segments with a different structure 
along a fibre can vary from several micrometers to 10 m and more – these are layers, 
pores, thickened and thinned parts, etc.    
Microstructure – means the supramolecular formations of the polymer, 
crystallites with different longitudinal and transverse dimensions, and the reciprocal 
position and state of the intercrystallite (amorphous) phase of the polymer. The size 
of the formations ranges from several tens of angstroms to up to 100 Å.  
The structure of the polymer in the fibre is established as it is fabricated in all 
stages of the process chain, from synthesis of the polymer to textile operations. [12] 
Articles made of fibre materials, such as drains, wound coverings, retaining 
bandages, etc., are widely used in medical practice. [13] 
The process of preparing fibres is called spinning. [10] The following chapters 
provide a description of some basic types of spinning. 
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2.1.1 Wet Spinning 
The process of wet spinning involves extrusion of a polymeric liquid through fine 
holes known as spinnerets. The polymer solution is spun into a coagulating solution to 
precipitate the polymer. This solution draws out the solvent and leaves behind only the 
polymer. The resulting fibres are oriented and the degree of crystallinity is increased. 
This has the effect of increasing the modulus and tensile strength of the fibres. This 
technique is required for polymers that require dissolving in a solvent to be spun. [14], 
[15] By wet spinning are prepared fibres for general household applications and also 
a different kind of industrial fibres (e.g. thermostable, heat-resistant). [12] This method 
is also suitable for natural polymers, for example, collagen, silk fibroin or chitosan. 
[16], [17], [18] 
2.1.2 Electrospinning 
Electro-spinning is a technology that enables the production of continuous fibres 
with dimensions in the range of nanometres to a few microns. These fibres possess high 
surface area to volume ratio, high porosity similar to the natural extracellular matrix 
(ECM), and other outstanding properties. Electro-spun fibres can be oriented 
or arranged randomly. [19], [20], [21] 
In process of electro-spinning, an electrical potential is applied between a droplets 
of a polymer solution and held at the end of the nozzle of the spinneret and a grounded 
collector plate. When the applied electric field overcomes the surface tension of the 
droplet, a charged jet of polymer solution, which is controlled by the electric field, 
is ejected. The ejected fibre jet is known as the Taylor cone. The ejected jet has bending 
instabilities caused by repulsive forces between the charges carried with the jet. The jet 
grows longer and thinner until it is collected on the collector plate as fibres. [21], [22] 
A variety of material can be used for electro-spinning including: biodegradable, 
non-degradable, natural and synthetic materials. For example, polymers used 
for electro-spinning, are alginate, cellulose, chitin, hyaluronic acid. [19], [21] The uses 
of electro-spinning can be found in various applications such as wound healing, 
scaffolds in tissue engineering, drug delivery, enzyme immobilization, biosensors, 
filtration, cosmetics, etc. [22] 
2.1.3 Dry spinning 
It is a process, in which a mixture of solvents and polymer is extruded through 
a die into a warm gas. As the material moves through the gas, it is heated and the 
solvents evaporate. The concentration of polymer increases and the jet solidifies into 
a fibre that is taken up by a roller at a speed higher than the extrusion speed. [23] 
Dry spinning is used to produce man-made fibres from polymers such as cellulose 
acetate, cellulose triacetate, polymers and copolymers of vinyl chloride, 
and acrylonitrile. [24] 
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2.1.4 Melt spinning 
Polymers that melt on heating without undergoing any decomposition are spun 
by a melt spinning system. [25] The molten polymer is extruded through spinnerets in 
a vertical chamber where the molten filaments are cooled with circulating air. Following 
the spinning stage, the extruded tow of filaments is subjected to a high degree 
of stretching to align the constituent polymers. This way the material achieves the 
required fibre fineness and usable tensile properties. [26] Typical polymers spun this 
way are polyamide 6, polyamide 6.6, and polyester fibres (poly(ethylene terephthalate)). 
[27] Fibres of biopolymer poly(3-hydroxybutyrate) were also prepared by this 
technique. [28] 
2.1.5 Biopolymers for spinning techniques 
Just like the nature has used the biological polymers as the material of choice, 
biopolymers can be the choice for fabrication new materials for man, also in the form 
of fibres, thanks to their properties and great possibility in application in medical field. 
[2], [29] Combination of fibres technology and medical sciences has resulted into a field 
called medical textiles. [30] Textile materials are suitable for many medical and surgical 
applications where a combination of strength and flexibility are required. [31] 
2.2 Biopolymers 
Biopolymers are polymers formed in nature during the growth cycles of all 
organisms; hence, they are also referred to as natural polymers. [32] These polymers 
offer the advantage of being similar to biological macromolecules, therefore 
the biological environment is prepared to recognize them and deal with these polymers 
metabolically. One of the many important properties of biopolymers is the similarity 
with the extracellular matrix (ECM). [33] They are generally non-toxic, even at high 
concentrations; biocompatible and biodegradable. On the other hand, many biopolymers 
have poor mechanical properties and are limited in supply, and can therefore be costly. 
[34], [35] 
Natural polymers can be obtained by the fermentation of micro-organisms, 
produced in vitro by enzymatic processes, the largest amount is extracted from plant. 
Living organisms are able to synthesize a variety of polymers. These polymers are 
divided into major classes according to their chemical structure: polysaccharides, 
proteins and polyesters. [33] 
Polysaccharides are polymeric carbohydrate structures, formed of repeating units 
(either mono- or di-saccharides) joined together by glycosidic bond. The structures are 
often linear, but may contain various degrees of branching. [35] The example 
of polysaccharide can be cellulose, starch, xanthan or hyaluronic acid.  
Proteins are specific copolymers with regular arrangements of different types 
of α-amino acids. Proteins are e.g. collagen, wool or silk. [32] 
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Polyesters are found in nature in a wide range of bacteria, higher plants and are 
also produced naturally in some animals. Example of polymer produced within 
the bacteria is poly(3-hydroxybutyrate) and shellac is polymer produced by animal. [37] 
Biopolymers can be used in traditional commodity, in agriculture, filtration, 
hygiene and protective clothing. However, the main application is in the medical field. 
The medical application include drug delivery systems, wound closure and healing 
products, surgical implant devices, and scaffolds for tissue engineering. [29] 
2.2.1 Biopolymer for spinning: Hyaluronic Acid 
Hyaluronic acid, as a biopolymer, is thanks to its great chemical and biological 
properties, natural appearance in a human body, and the possibility of obtaining it 
from various natural sources a very attractive subject for biotechnology, and medicine 
in general. Hyaluronic acid is an important material in wound healing, for example 
Laserskin®, which is maximally-esterified hyaluronic acid with perforations or it can 
serve as an anti-inflammatory component in the wound dressing materials. [7], [38] 
The combination of spinning techniques and hyaluronic acid can bring new 
possibilities in preparation of new types of wound dressing materials.  
2.3 Hyaluronic acid 
Hyaluronic acid (HA, hyaluronan, sodium hyaluronate) is a naturally occurring 
biopolymer with unique advantages, it is easy to produce and modify, and it is used 
across a wide variety of medical fields and in cosmetic practice. 
Hyaluronan belongs to a group of substances known as glycosaminoglycans 
(GAGs), being structurally the most simple amongst them, and the only non-sulfated 
one. [7], [38], [39] 
2.3.1 Properties and structure of hyaluronic acid 
Hyaluronic acid (HA) is a linear and anionic polymer which consists of two 
modified sugars, D-glucuronic acid and N-acetyl-D-glucosamine (Figure 1). They are 
linked together through alternating beta-1,4 and beta-1,3 glycosidic bonds. [38] Both 
sugars are spatially related to the glucose which in the beta configuration allows all 
of its bulky groups: the hydroxyls, the carboxylate moiety and the anomeric carbon 
on the adjacent sugar, to be in sterically favourable equatorial positions. At the same 
time, all of the small hydrogen atoms occupy the less sterically favourable axial 
positions. For this reason, the structure of the disaccharide is energetically very stable. 
[40] The functional groups (carboxylic acids and alcohols) along the backbone can be 
used to introduce the functional domains or to form a hydrogel by crosslinking. [41] 
 
 13
 
 
Figure 1 Structure of the disaccharide repeating unit of hyaluronic acid. [38] 
In aqueous solution, HA forms tertiary structures β sheets based on 2-fold helixes 
anti-parallel hyaluronan chains. Sphere occupied by HA molecule is quite large, but not 
impenetrable. Therefore, HA forms specific overlapping domains creating meshwork 
which is stabilized by specific H-bonds (up to five H-bonds per tetrasaccharide unit 
of HA), water bridges and hydrophobic interactions. The actual mass of hyaluronan 
within this domain is very low, and small molecules such as water, electrolytes 
and nutrients can diffuse freely through solvent, within the domain. Large molecules 
such as proteins will be partially excluded from the domain because of their 
hydrodynamic sizes in solution. [42] Hyaluronan’s polarity and the formation of such 
a meshwork is a potential reason for the higher osmotic pressure in solution which is 
the cause of hyaluronan’s high water retention capacity. [43], [44] 
HA in aqueous solution undergoes a transition from Newtonian to non-Newtonian 
characteristics with increasing molecular weight, concentration or shear rate. [45] 
HA is in the form of sodium salt in physiological conditions, because at pH 7, 
the carboxyl groups are predominantly ionized. The hyaluronan molecule is a polyanion 
that has associated exchangeable cation counterions to maintain charge neutrality. [42] 
In this case is HA referred to as sodium hyaluronate. [46] The backbone of a hyaluronan 
molecule in a physiological solution is stiffened by a combination of the chemical 
structure of the disaccharide, internal hydrogen bonds, and interactions with solvents. 
The preferred shape in water features hydrophobic patches on alternating sides of the 
flat, tape-like secondary structure. [40], [42] 
HA has a range of molecular sizes from 1000 to 10,000,000 Da with the average 
length of a disaccharide approximately 1 nm. However, the molecular weight depends 
on the source of HA. [47], [40], [45] 
Hyaluronic acid is enzymatically degraded by enzyme hyaluronidase and is 
completely resorbable through multiple metabolic pathways. [39] Enzymatic 
degradation cleaves the HA macromolecule into HA fragments of precisely defined size 
for the desired biological function. HA can also be naturally degraded in the organism 
by reactive oxygen species. [46] As a very large molecule, hyaluronan is prone to 
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mechanical degradation either by ultrasonic treatment or by thermal degradation 
at elevated temperatures. [42] 
When HA is not bound to other molecules; it binds to water and forms highly 
viscous solutions. [40], [48]  Hydration and/or water holding capacity is one of the most 
important aspects of the HA function. [49] HA can immobilize water in tissue 
and thereby change dermal volume and compressibility. [38] 
It has several important biological functions in mammal bodies. In the body, it 
plays a critical role as a signalling molecule in cell motility, cell differentiation, wound 
healing. Native HA degrades rapidly and resides within the tissue only for 1-2 days. 
[40], [43], [50], [51] HA shows some pH sensitivity in aqueous environment, especially 
when it is cross-linked to produce drug delivery systems like hydrogels or micro (or 
nano) particles. [16] 
Large matrix polymers of HA are space-filling, anti-angiogenic, 
and immunosuppressive. The intermediate-sized polymers, which consist of 
25-50 disaccharides, are inflammatory, immunostimulatory, and highly angiogenic. 
Smaller oligosaccharides are antiapoptotic and induce heat shock proteins. [38] 
Hyaluronic acid however possesses poor mechanical properties. [51] 
2.3.2 Synthesis, production 
Commercially produced HA is isolated either from animal sources, within 
the synovial fluid, umbilical cord, skin, and rooster comb, or from bacteria through 
a process of fermentation or direct isolation. [45] 
2.3.3 Occurrence of HA 
Hyaluronic acid is almost omnipresent in the human body and in other 
vertebrates; it is also present in the capsules of some bacteria. HA is absent in fungi, 
plants and insects. It primarily occurs in the ECM and pericellular matrix, it is also 
a major intracellular component of connective tissues such as skin, the synovial fluid 
of joints, vitreous fluid of the eye, the scaffolding within cartilage and the umbilical 
cord. 
Significant amounts of HA are also found in lung, kidney, brain, and muscle 
tissues. [40] The highest content of HA in the human body is in the synovial fluid, 
umbilical cord, and vitreous fluid of the eye.  
By far, the largest content of HA is found in rooster combs. [38], [52] The 
concentration of HA in rooster comb is 7.5 mg·mL-1, in the synovial fluid 3-4 mg·mL-1, 
in umbilical cord 3 mg·mL-1, in the vitreous humor of the eye 0.2 mg·mL-1, and in skin 
0.5 mg·mL-1. The largest deposit of hyaluronan resides in the skin; in an adult human 
this totals ~ 8 g. [42] 
2.3.4 Medical Application 
Preparations of hyaluronan or higher crosslinked products are used for many 
medical applications. [42] 
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2.3.4.1 Wound healing and scarring 
As the HA is naturally present in the skin and soft connective tissues, it is 
an appropriate choice for a matrix to support dermal regeneration and augmentation. 
[40] Hyaluronic acid is also involved in the process of wound repair. During wound 
healing, HA promotes epithelial migration and differentiation, improves angiogenesis, 
and enhances collagen production. A 100 % benzyl-esterified derivative of hyaluronic 
acid processed into fibres and prepared as a flat, non-woven pad dressing, which can be 
seeded with fibroblasts before application was manufactured. [53] According to 
Prestwich and co-workers, crosslinked HA gel films accelerate the healing of full-
thickness wounds, presumably by providing a highly hydrated and nonimmunogenic 
environment. HA scaffolds have been also used in burn care or for difficult-to-heal 
wounds. [40] 
2.3.4.2 Adhesion prevention 
Most surgical procedures are accompanied by undesired tissue damage, which can 
lead to abdominal tissue adhesion. It is a complex inflammatory condition that can 
cause pain and impact organ function. For example, a new, internally-esterified 
material, the HA autocrosslinked polymer hydrogel, is effective in reducing postsurgical 
adhesions in laparoscopic surgery. [42], [47], [54]  
2.3.4.3 Drug delivery 
HA is usually conjugated or coated with the chemical drug or polymer to enhance 
therapeutic efficiency as well as to provide sustained release properties. For example, 
HA has been used for targeting specific intracellular delivery of genes or anticancer 
drugs. The HA has also found an application in ocular, nasal or parenteral delivery. It is 
used in ocular delivery because of its nonirritating property and high water-binding 
capacity. The absorption of drugs and proteins via mucosal tissues could be enhanced 
thanks to the mucoadhesive properties of HA in the nasal drug delivery systems. [55] 
Generally, HA is thought to act as either a mucoadhesive and retain the drug at its site 
of action/absorption or to modify in vivo release/absorption rate of the therapeutic 
agent. [45] HA can be combined with partner molecules (such as isopropylacrilamide, 
polyacrylic acid or cellulose) and different biophysical properties for various 
applications can be obtained. [7] 
2.3.4.4 Orthopedic surgery 
HA provides necessary lubrication for the joint and serves as shock absorber. It 
reduces the friction of the moving bones and diminishes wear of the joint. [38] 
Administration of purified high molecular weight HA into orthopaedic joints can restore 
the desirable rheological properties and alleviate some of the symptoms 
of osteoarthritis. [45] A HA gel has been successfully trialled as a carier mechanism 
for antibiotics to the eye and injection of chondroitin sulphate and HA mixture prevents 
endothelial damage from air bubbles created intraoperatively. [7] 
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2.3.4.5 Ophthalmics  
HA is commonly used in ophthalmology for the dry eye treatment and as 
a viscoelastic device in ophthalmologic surgery owing to the ability to form highly 
viscous solutions even at low concentrations. [56] During the ophthalmologic surgery 
(cataract surgery or deep lamellar keratoplasty) intracameral injection of viscoelastic 
HA can maintain anterior chamber length and protect the corneal endothelium. [57] 
2.3.4.6 Other medical applications 
Hyaluronic acid is also used in clinical medicine as a diagnostic marker for many 
diseases including cancer, rheumatoid arthritis and liver pathologies. [38] In form 
of implants, as a filling material, it is used to treat conditions as urinary incontinence, 
otolaryngology or reconstructive surgery. HA based scaffolds in combination with other 
materials have been investigated, for example freeze dried chitosan/HA, freeze dried 
HA/collagen scaffolds, or freeze dried glutaraldehyde crosslinked HA/polyglycolic acid 
scaffolds. These scaffolds were prepared for bone and cartrilage repair and regeneration. 
[41] 
2.4 Crosslinking 
Crosslinking is process of intermolecular binding, in which previously separated 
molecules are bonded with permanent chemical bonds. The crosslinking firstly results 
in a slight increase in molecular weight, and then forms a network. The crosslinking can 
modify many of the physical properties of a polymer. Especially the mechanical 
properties of long chain polymers depend not only on chemical structure and chain 
mobility, but also on the association between adjacent molecules. [58] 
Polymeric materials can be divided into two main categories, dependent on their 
molecular weight: polymers with molecular weight higher than about 105 g·mol-1 
and polymers which have low molecular weights, lower than 104 g·mol-1, often in the 
range 2-3·103 g.mol-1. Polymer materials in the lower molecular-weight range often 
require a crosslinking step to obtain satisfactory mechanical properties. 
Different types of crosslinking are possible:  
Covalent crosslinking, which is regarded as the most stable; 
Ionic bonds; 
Physical crosslinking, via Van der Waals, hydrogen bonds, or other interactions. 
[59] 
Physical and ionic crosslinking occurs in solutions of high molecular weight HA. 
These two crosslinking mechanisms are difficult to control, which limit the final 
network structure and properties. [60], [61] 
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2.4.1 Chemical crosslinking 
In general, it is the process of chemically joining two or more molecules by 
a covalent bond. Modification involves attaching or cleaving chemical groups to alter 
the solubility or other properties of the original molecule. [62] 
The crosslinking reactions have been accomplished under acidic, neutral, 
and alkaline conditions. [41] 
2.4.1.1 Crosslinking reagents 
Crosslinking reagents contain two or more reactive ends that are capable 
of attaching to specific functional groups on molecules [62] Crosslinkers can be divided 
in two groups: homobifunctional crosslinkers, and hetrobifunctional crosslinkers. 
Homobifunctional crosslinkers are molecules that have the same reactive groups 
on each end of the crosslinker. These crosslinkers can also create intramolecular 
crosslinks. Heterobifunctional crosslinkers are molecules that have different reactive 
groups on each end of the crosslinker. They are more selective and work in a two-step 
process. [63] 
2.5 Crosslinking of HA 
When HA is crosslinked, different HA chains are linked together by two bonds 
or more, as shown in Figure 2. Crosslinking procedures can be: direct crosslinking, 
crosslinking of HA derivates and crosslinking of different HA derivates. [46] 
The density of prepared HA network depends on the degree of crosslinking that is 
achieved. [64] Hyaluronan has four reactive groups: acetamido, carboxyl, hydroxyl 
and the reducing end. These groups have the ability for crosslinking to itself or other 
polymers. [65] The main responsibility for crosslinking of HA molecules have the 
hydroxyl and carboxyl functional groups. Hydroxyl groups may be crosslinked via 
an ether linkage and carboxyl groups via an ester linkage. The process of crosslinking is 
the most common modification of hyaluronan to form a hydrogel.  
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Figure 2 Chemical crosslinking of polymer. [46] 
 
HA may be treated with acid or base and this treatment will results in at least 
partial  deacetalization, resulting in the presence of free amino groups. 
Amino groups may be crosslinked via an amide (-C(O)-NH-); imino (-N=CH-) 
or secondary amine (-NH-CH-) bond. An imino linkage can be converted into an amino 
linkage in the presence of a reducing agent. [66] 
Since HA is soluble in water, crosslinking can be performed in aqueous 
conditions. However, some reactions are pH-dependent and need to be performed 
in acidic or alkaline conditions, which induce significant HA chain hydrolysis. [46] 
The agents already used for crosslinking of HA are 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC), N-hydroxysuccinimide (NHS), 
glutaraldehyde (GTA), divinyl sulfone (DVS), poly(ethyleneglycol) diglycidyl ether 
(PEGDG), butanediol-diglycidyl ether (BDDE) and many others. [46], [67], [68], [69] 
Formulas of these reagents are in the Table 1. General crosslinking agents for HA 
chains usually include carbodiimides, hydrazides, aldehydes, sulfides, 
and polyfunctional epoxides. Chemical modification of HA enables the polysaccharide 
to be used for various biomedical applications. [64] 
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Table 1 Chemical formulas of the crosslinking reagents. [70], [71],[72], [73], [74] 
EDC NHS 
  
 
 
 
 
 
 
GTA DVS 
 
 
ADH BDDE 
 
 
 
 
 
 
 
 
 
2.5.1 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) 
EDC is a water-soluble, highly efficient “zero-length” crosslinker, which does not 
bind to HA molecules; it just activates the carboxyl group of HA. [46], [75], [76] EDC 
reacts with carboxylic acid groups to form an active O-acylisourea intermediate, which 
is very short-lived and readily undergoes rearrangements. The second step is the 
nucleophilic attack by the amine on the activated HA. An amide bond is formed 
between the primary amine and the original carboxyl group. An EDC by-product is 
released as a soluble urea derivate. The O-acylisourea intermediate is unstable 
in aqueous solutions, it reacts with water and it quickly rearranges into a stable N-acyl 
urea byproduct. The intermolecular formation of ester bonds between the hydroxyl 
and carboxyl groups of HA is observed. [46], [76], [77] In general, EDC is preferable 
among the crosslinking reagents because it can induce crosslinking of biomaterials 
simply by changing them into water-soluble urea derivates that have very low 
cytotoxicity. [78] The crosslinking reaction is shown in Figure 3. 
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Figure 3  Crosslinking reaction scheme of HA with EDC. [76] 
2.5.2 N-hydroxysuccinimide (NHS) 
NHS is a homobifunctional one of the most common used crosslinker. [79] This 
reagent is used with EDC reagent in order to prevent the formation of the irreversible N-
acylurea by-product (Figure 4). The use of EDC together with NHS causes a formation 
of more hydrolysis-resistant and non-rearrangeable intermediates. [46] HA-N-
succinimide is an activated ester of the glucuronic acid moiety and this HA-active ester 
intermediate is a precursor for crosslinked hydrogels. [80] 
 
Figure 4 Crosslinking of HA with EDC and NHS. [46] 
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2.5.3 Glutaraldehyde (GTA) 
Glutaraldehyde is in water soluble crosslinker ans it is believed to form either 
a hemiacetal or an ether link with HA under acidic conditions (Figure 5). 
Glutaraldehyde has been widely use for crosslinking of proteins such as collagen and 
gelatine, but it has been found out that HA readily undergoes crosslinking with GTA 
when a film of HA is subjected to the crosslinking reaction. [66], [81] However, GTA is 
generally considered to be toxic, thus it requires specific handling during the reaction 
and purification of final product. [46], [82]  
 
Figure 5 The OH group on the hyaluronic acid reacts under acidic conditions with 
glutaraldehyde giving hemiacetal or ether ether crosslinks. [66] 
2.5.4 Divinyl sulfone (DVS) 
DVS crosslinker causes the occurance of the crosslinking via the hydroxyl groups 
forming an ether bond (Figure 6). [66] The hydroxyl groups of the HA chains react to 
form an infinite network of sulfonyl bis-ethyl crosslinks. DVS reacts readily with HA in 
aqueous alkaline solutions at room temperature. The reaction is fast, and strong gels are 
obtained within minutes. DVS crosslinking does not involve the biologically reactive 
functional groups on the HA molecule, thus the prepared gels largely retain 
the biological properties of native HA. Hyaluronic acids which are chemically 
crosslinked with DVS are called hylans. [41], [83]  
 
Figure 6 The OH group on the hyaluronic acid reacts under alkaline conditions with 
DVS to give sulgonyl bis-ethyl crosslinks. [66] 
2.5.5 Adipic dihydrazide (ADH)  
ADH is a water-soluble homobifunctional crosslinikng reagent that provides 10-
atom bridge between crosslinked molecules. [84] Covalent attachment of this reagent to 
the carboxylic acid groups of HA under mild conditions results in the availability 
of pendant hydrazide amino functionalities arrayed along the hyaluronate backbone. 
[85] The reaction of HA with this crosslinking reagent is shown in Figure 7. 
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Figure 7 Illustration of crosslinking reaction of hyaluronan with adipic dihydrazide. [86] 
2.5.6 Butanediol-diglycidyl ether (BDDE) 
BDDE is a bifunctional crosslinker that reacts with HA’s primary hydroxyls. The 
reaction consists of the epoxide ring opening to form ether bonds with the HA hydroxyl 
groups. Crosslinking is accomplished simply by mixing HA with BDDE in water 
and appropriately adjusting the temperature and pH. [46], [87] This crosslinking reagent 
is already used in commercialized formulations of HA as dermal filler. [88] Figure 8 
shows reaction of BDDE with HA in alkaline and acidic conditions. 
 
Figure 8 HA crosslinking with BDDE in alkaline conditions (a), and in acidic conditions 
(b.). [46] 
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2.6 Goal of the work 
The main goal of this study is the preparation of water insoluble microfibres 
from HA, using the method of wet spinning. The fibres are crosslinked with EDC 
or combination of EDC and NHS crosslinking reagents and the goal of the work also 
involves the characterization and comparison of prepared fibres and optimization 
of conditions for preparation of stable fibres.  
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3 EXPERIMENTAL PART 
3.1 Chemicals 
• Sodium hyaluronate (1500-1750 kDa) was purchased from  
Contipro Biotech s.r.o. (CZ) 
• N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride was 
obtained from Sigma-Aldrich (Germany) 
• N-Hydroxysuccinimide was obtained from Sigma-Aldrich (Germany)  
• Sodium hydroxide (P.A.) was purchased from Lach-Ner s.r.o. (CZ) 
• Methanol (P.A.) was supplied from Lach-Ner s.r.o. (CZ) 
• Ethanol (96 %) was purchased from Moravian distillery, Kojetín (CZ) 
• Acetic Acid (G.R., 99.8 %) was purchased from Lach-Ner s.r.o. 
• Phosphate buffer saline with pH = 7.4, phosphate buffer saline with 
pH = 3 and phosphate buffer saline with pH = 11 were prepared using KCl 
(P.A.) obtained from Lachema; NaCl (P.A.) obtained from Lach-Ner s.r.o.; 
KH2PO4 was obtained from Lachema and HNa2O2P·12 H2O (P.A), was 
obtained Sigma-Aldrich. pH was adjusted by HCl (c = 1 mol.dm-3, G.R., 
35-38 %) and NaOH (c = 1 mol.dm-3), both were purchased from Lach-
Ner s.r.o. 
3.2 Equipments 
• Thermogravimetric Analysis (TGA Q 500, TA Instruments) 
• Stress-Strain Tester (Zwick Z 010, Roell) 
• Fourier Transform Infrared Spectroscopy (Tensor 27, FTIR BRUKER) 
• D-8 Advance diffractometer (Bruker AXS, Germany) 
• Scanning electron microscope (SEM MIRA3, TESCAN) 
• pH Meter S2K712 ISFETCOM JAPAN 
• Analytical scale Denver Instrument SI-234A 
• Magnetic stirrer IKA® RCT basic  
• Steel syringe for wet spinning 
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3.3 Methods 
3.3.1 Preparation of Hyaluronan Fibers  
Sodium hyaluronate (1500-1750 KDa, 6 g) was dissolved under stirring in 94 g 
of water with the addition of NaOH (0.64 g) to obtain homogenous, well-flowing 
viscous solution suitable for spinning. This solution was pressed (wet-spinning 
technique; Figure 9) through a nozzle with the diameter of 0.4 mm to the coagulation 
bath having the composition: 600 ml of methanol and 400 ml of acetic acid (98 %). The 
prepared fibres were left in the coagulation bath for 15 hours, then washed with absolute 
methanol and dried.  
 
 
 
 
 
Figure 9 Photograph of wet-spinning machine; (a) pump part, (b) hyaluronan solution, (c) 
needle, (d) coagulation bath. 
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3.3.2 Preparation of Crosslinking Solution 
Different concentrations of EDC were prepared in ethanol (5, 25, 50 
and 100 mmol/L) and mixture solutions from EDC and NHS were prepared in ethanol 
(EDC/NHS, 25/12.5 and 50/25 mmol/L) respectively. The prepared solutions were kept 
in fridge at 4 °C. 
3.3.3 Crosslinking of water soluble hyaluronan fibres with EDC and EDC/NHS 
Aqueous mixtures containing an organic solvent (ethanol) of various 
concentrations of EDC and EDC/NHS were prepared. The water soluble hyaluronan 
fibres were immersed into the mixtures of the crosslink EDC, EDC/NHS for different 
time at room temperature.  After crosslink with a reaction time of 0.5, 1, 4, 8, 12, 24, 
48 h the samples were washed three times with methanol with the change of the solution 
every 30 min and dried in the air. 
 
3.3.4 Preparation of Samples for Mechanical Tests 
For testing mechanical properties of fibres, paper constructions with parameters 
of 4.5 x 2 cm were prepared, as shown in Figure 10. A single fibre was glued on to the 
construction, and for each tested type of fibre, three samples were prepared. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 Paper construction with fibre for mechanical tests. 
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3.4 Characterization 
3.4.1 Swelling Tests 
Swelling tests were performed using analytical scale, in phosphate buffer solution 
(PBS) at different pHs: 7.4, 3 and 11. The sample of the fibre, prepared as stated 
in chapter 3.3.3., of approximately 1 cm was weighted with the vial before immersing 
in PBS solution and after certain times. Every time, the vial was gently dried with small 
piece of paper before weighing. The swelled fibre with vial was weighted after 
following times: 1 min, 3 min, 5 min, 10 min, 15 min, 30 min, 45 min, 1 h, 3 h, 5 h, 
12 h, 24 h, and 48 h. The swelling ratio was calculated according to equation 1. 
 
% =
	
	
∙ 100                                               (1) 
 
Where ww is the weight of wet fibre and wd is the weight of dry fibre. 
3.4.2 Thermal Analysis  
Samples were studied using TGA Q 500 (TA Instruments) under heating rate 
of 10 °C·min-1. The test temperature range was from room temperature to 600 °C 
with the sample mass of about 5–10 mg under 40 ml·min-1 nitrogen atmosphere. The 
alumina crucible was used for all measurements. 
3.4.3 Fourier Transform Infrared Spectroscopy (FTIR) 
Attenuated total reflectance Fourier transforms infrared spectroscopy was 
performed by using a Tensor 27 spectrophotometer (FTIR BRUKER) equipped 
with a diamond crystal for the ATR-FTIR spectroscopy. The wavenumber range was 
between 4000 cm-1 and 650 cm-1 with the resolution of 4 cm-1 and the number of scans 
equal to 32. 
3.4.4 Testing of Mechanical Properties 
Experimental tests were performed on a Zwick Z 010 testing machine (Roell) 
with a 500 N force load cell. Tests were performed at a crosshead speed of 5 mm·min-1 
with jaws for tensile testing, and the pre-load of 0.05 N for 60 s. The samples were 
in paper construction, as stated in chapter 3.3.4. 
3.4.5 Scanning Electron Microscope (SEM) 
The images of samples were done at the electron scanning microscope MIRA3 
(Tescan). Before recording the photographs, samples were coated with 24 nm film 
of gold. Accelerating voltage HV 5 kV and detector of secondary electrons were used. 
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3.4.6 X-Ray Diffraction (XRD) 
X-ray diffraction was collected on a device namely; D-8 Advance diffractometer 
(Bruker AXS) with Bragg-Brentano θ-θ goniometer (radius 217.5 mm) equipped with 
a secondary beam curved graphite mono-chromator and Na (Tl) I scintillation detector. 
The generator was operated at 40 kV and 30 mA. The scan was completed at room 
temperature from 5 to 60° (2θ) in 0.02° step with a counting time of 8 s per step.  
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4 RESULTS AND DISSCUSSION 
EDC and NHS were used for the first time to crosslink water soluble hyaluronan 
fibres through chemical interaction.  Many parameters were studied to optimize 
the condition of crosslink like concentration of EDC, concentration of NHS, time 
of reaction. The properties of prepared fibres were studied by chosen types 
of characterization. 
4.1 Characterization by Swelling Tests 
The swelling ratio was determined by the swelling tests. The tests were held 
maximal for 48 hours. The most stable samples were fibres crosslinked for 12, 24 
and 48 hours in the solution with concentration of 100 mmol/L EDC. These fibres were 
stable for 48 hours in pH 7.4, but the less time of crosslinking, the fibre was more 
fragile and torn into pieces. In ph 3 were all of these three samples equally stable. 
Comparable to this sample were fibres crosslinked for 48 hours in solutions 
with concentrations of 50 mmol/L EDC and 50 mmol/L EDC and 25 mmol/L NHS. 
In general for all other fibres, the less time of crosslinking and the lower 
concentration of crosslinking solution, the lower stability they had. In pH 3, the fibres 
were stable equally or a little longer time than in the solution with pH 7.4. 
In pH 11, the samples were stable only for few minutes; they usually hydrolyzed 
after ten or fifteen minutes. The most stable sample was the fibre crosslinked in the 
solution of 100 mmol/L for 48 hours, which hydrolyzed after 15 minutes. 
In Figure 11 is shown dependence of swelling ratio on time of sample which was 
crosslinked 48 hours in 100 mmol/L EDC solution. Samples were stable 48 hours 
in PBS solutions with concentrations 7.4 and 3, in PBS solutions with concentration 11 
was fibre stable only 15 minutes. 
 
 
 
 
  
Figure 11 Result of swelling test 
4.2 Characterization by Thermogravimetric Analysis
Thermal stability 
In Figure 12 are displayed TGA curves and theirs derivations of fibre before 
crosslinking and fibre crosslinked 48
observed at range from 25 to approximately 1
of water either weakly bound to the surface or trapped within the polymer chains and 
the elimination of other volatile components (the tracks 
used for washing). At the temperature higher than 185
degradation, and the second mass loss starting at about 430
of traces of inorganic materials, probably from treatment of fibres.
highest rate of change of mass
slightly higher than the one for fibre before crosslinking (204.05
the thermal stability has increased.
for sample crosslinked for 48 h in the solution of 
100 mmol/L of EDC. 
 
of fibres was studied by TGA Q 500 
 hours in 100 mmol/L EDC solution. 
90 °C was attributed to the elimination 
of coagulation bath or 
 °C starts the onset 
 °C is due to the degradation 
 Temperature for the 
 from first derivation for crosslinked fibre (204.96
 °C), which means, that 
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(TA Instruments). 
The mass loss 
to 
methanol 
of sample 
 °C) is 
 Figure 12 TGA cur
fibre crosslinked 48
The determined values of temperatures when the degradation process has started 
(onset temperatures, TONSET
obtained through first derivation of TGA curves are given in Table 2. 
The results show, that temperatures for the highest rate of 
increasing from fibres crosslinked with the highest concentration of crosslinking
to fibres crosslinked with the lowest concentration of reagent. It means, that fibres 
crosslinked with lower concentration of crosslinking reagent and for shorter time are 
more thermally stable than samples crosslinked for longer time with higher 
concentration of reagent. This
which are in general bonds with low stability, caused by crosslinking
of these weak ester bonds are formed when higher concentration of reagent is used 
and when the crosslinking treatment is longer. This could be the reason, why fibres 
crosslinked with higher concentrations of reagents and for longer time have lower 
thermal stability than the ones crosslinked with lower concentrations and for shorter 
time.  
ve and first derivation of TGA curve of fibre before crosslinking and 
 h in 100 mmol/L EDC. 
) and temperatures for the highest rate of change of mass
change of mass
 effect is probably due to the formation of ester bonds, 
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Table 2 Results of thermogravimetrical analysis of chosen samples. 
5 mmol/L EDC 
Time of crosslinking 0 h 1 h 12 h 24 h 48 h 
TONSET (°C) 191.20 195.47 193.97 193.14 194.72 
T1 (°C) 204.05 211.94 210.27 207.21 209.56 
25 mmol/L EDC 
Time of crosslinking 0 h 1 h 12 h 24 h 48 h 
TONSET (°C) 191.27 191.98 192.43 194.16 193.33 
T1 (°C) 204.05 206.12 206.94 209.40 208.84 
25 mmol/L EDC, 12.5 mmol/L NHS 
Time of crosslinking 0 h 1 h 12 h 24 h 48 h 
TONSET (°C) 191.27 191.77 192.03 193.12 192.45 
T1 (°C) 204.05 205.96 206.27 208.23 206.73 
50 mmol/L EDC 
Time of crosslinking 0 h 25 min 24 h 48 h 
TONSET (°C) 191.27 194.22 194.09 191.36 
T1 (°C) 204.05 210.83 210.35 205.13 
50 mmol/L EDC, 25 mmol/L NHS 
Time of crosslinking 0 h 25 min 48 h 
TONSET (°C) 191.27 194.46 191.59 
T1 (°C) 204.05 210.89 205.25 
100 mmol/L EDC 
Time of crosslinking 0 h 1 h 12 h 24 h 48 h 
TONSET (°C) 191.27 191.75 192.13 191.63 191.68 
T1 (°C) 204.05 205.08 206.10 204.92 204.96 
 
4.3 Characterization by Fourier-transformed Infrared Spectroscopy 
The new types of bond linkages were determined using infrared analysis 
with ATR mode.  All the following spectra are normalized. 
4.3.1 Powder of Sodium Hyaluronan and Hyaluronan Fibre Before Crosslinking 
In Figure 13 are displayed whole spectra of sodium hyaluronate powder and fibre 
before crosslinking. In general, at 3600-2800 cm-1 is the region of CH, NH, and OH 
 stretching vibrations. The peaks at the end of the spectra are typical for bonds C
C-C, C-H. However, the region of interest is the area between 1500 and 1800
In this area, peaks for esterification and amidation appear. 
In Figure 14 is shown section of infrared spectra of sodium hyaluronate powder 
and fibre before chemical crosslinking.
to the formation of ester bond between the molecules of HA; probably caused by a so 
called eternal esterification. This happened after the wet spinning and the coagulation 
in the mixture of acetic acid/methanol, the es
HA are formed. Area at around 1550
has decreased and the peak for amidation has occurred (1630
for peak at 1563 cm-1 has also increased, and it is 
respectively). 
 
 
 
Figure 13 Complete infrared spectra comparing powder of sodium hyaluronate and 
 
 New peak at 1733 cm-1 appears. This peak is due 
ter bonds between disaccharide units of 
 cm-1 shows that the peak for COO
 cm
area for amidation too (or for amines 
hyaluronan fibre before crosslinking. 
33
-O-C, 
 cm-1. 
2-
 (1607 cm-1) 
-1).  The intensity 
 
 4.3.2 Fibres after the treatement with crosslinking reagents
New peak at cca 1
(more ester bonds are formed). With the longer time of crosslinking, the peak for ester 
bond at approximately 1730
1700 cm-1 is increasing. This is because of the effect of crosslinking reagent; the longer 
time of crosslinking, the more ester bonds 
for every concentration, however, with the concentration of 25
and 25 mmol/L EDC and
and 48 hours of crosslinking. In the case of samples crosslinked with only 
the concentration of 5 mmol
treatment. The amidation peaks occu
crosslinking. The example of this effect is
from complete infrared spectra
by 100 mmol/L EDC. 
 
 
 
 
 
Figure 14 The section of infrared spectra comparing powder of sodium hyaluronate and 
 
700 cm-1 is the result of esterification after treatment with EDC 
 cm-1 is decreasing and the peak at approximately 
are formed. This appearance is same 
 12,5 mmol/L NHS, the peak for ester bond shows up after 24 
/L of crosslinking reagent, this peak occurs 
rred similarly as in case of fibre before 
 shown in the Figure 15, which is a section
 of fibre before crosslinking and fibres treated 
 
hyaluronan fibre before crosslinking. 
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 mmol/L EDC 
after 24 hour 
 
 4.4 Characterization of Mechanical Properties
Mechanical properties were characterized by 
(Roell). The following values were determined: Youngs modulus, tensile strength 
and strain at break. The data are, however, very variable, and no dependence is visible. 
The reason for this behaviour is probably the high heterogeneity of fibres. 
are determined values of Youngs modulus, tensile strength and strain at break
average values of three measurements for each fibre)
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 The section of infrared spectra comparing fibres crosslinked in the solution 
with concentration of 100
 
 
testing machine
.  
 mmol/L EDC and hyaluronan fibre before crosslinking.
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 Zwick Z 010 
In the Table 3 
 (the 
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Table 3 Determined values for E-modulus, strength and strain at break. 
Fibre E-Modulus 
[GPa] 
Strength 
[MPa] 
Strain at 
Break [%] 
HA before 13.15 470.04 13.66 
5 mmol/L 1h 9.28 459.09 17.91 
5 mmol/L 12h 6.97 367.14 16.59 
5 mmol/L 24h 3.16 396.32 19.56 
5 mmol/L 48h 7.83 328.11 8.06 
25/0 mmol/L 1h 9.44 404.68 14.32 
25/0 mmol/L 12h 5.98 501.95 13.66 
25/0 mmol/L 24h 5.26 422.27 24.34 
25/0 mmol/L 48h 12.58 556.62 11.75 
25/12.5 mmol/L 1h 8.31 374.34 12.93 
25/12.5 mmol/L 12h 11.37 383.13 8.90 
25/12.5 mmol/L 24h 6.88 351.04 10.08 
25/12.5 mmol/L 48h 6.90 439.57 14.19 
50 mmol/L 25 min 3.60 103.42 12.77 
50 mmol/L 48 h 14.12 571.91 12.08 
50/25 mmol/L 25 min 4.63 499.53 7.12 
50/25 mmol/L 48h 13.40 439.57 8.68 
100 mmol/L 1h 4.33 401.28 10.51 
100 mmol/L 12h 12.94 445.70 12.11 
100 mmol/L 24h 7.16 357.62 18.27 
100 mmol/L 48h 11.20 468.31 10.53 
 
 
 
 
 In the following Figure 
The curves exhibit a linear elastic behaviour up to approximately 0.3
consequently shallow yield point is observed and quasi plateau area.
curves is the break point.
crosslinked 48 hours in 100
course as the previous sample.  
Figure 
16 are displayed tensile curves of pure hyaluronan fibre. 
 For example are shown also stress-strain curves of fibre 
 mmol/L EDC (Figure 17), where the curves have similar 
 
 
 
16 The stress-strain curves of fibres before crosslinking.
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 % of strain, 
 The end of the 
 
 The determined E-
is shown in Figure 18
after 48 hours of treatment in solutions of all concentrations. As stated before, no 
dependence has occurred, probably due to 
which influenced the results of mechanical tests.
  
Figure 17 The stress
modulus in dependence on concentration of crosslinkin reagent 
, where are compared fibre before crosslinking and fibres 
the different diameter of prepared fibres, 
 
-strain curves of fibres crosslinked for 48 hours in solution with 
concentration of 100 mmol/L EDC. 
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 Figure 18 E-Modulus of sample before crosslinking (0) and samples crosslinked for 
48 hours. The concentrations are given under the columns in mmol/L.
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4.5 Characterization by Scanning Electron Microscopy 
Figure 19 shows the pictures from scanning electron microscope and cross-section 
of pure hyaluronan fibres before and after crosslink with EDC and EDC/NHS mixture. 
Pure hyaluronan fibre before crosslink (A, B) has relatively smooth surface 
morphology. Hyaluronan fibres after crosslink with EDC without and with NHS 
at room temperature with concentration of EDC 100 mmol/L, and ratio between EDC 
and NHS was (2:1)  are shown in figures (C, D, E, F) respectively. It is clear 
from figures (C, E) that hyaluronan fibre after crosslink have similar surface like 
the fibre before crosslinking. Pictures of cross-sections  (B, D, F) prove, that diameter 
of fibres is not of regular shape, but is very variable.  
 
Figure 19 SEM photographs of surface and cross-section of hyaluronan fibre before 
crosslinking and after crosslinking. Pure hyaluronan fibre (A), the cross-section of pure 
hyaluronan fibre (B), hyaluronan fibre crosslinked with 50 mmol/L EDC and 25 mmol/L 
NHS (C) and the cross-section of this fibre (D), hyaluronan fibre crosslinked with 
100 mmol/L EDC (E) and its cross-secion (F). 
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4.6 XRD 
Figure 20 shows XRD of hyaluronan fibre before crosslinking, and fibres 
crosslinked for 1 hour in solutions with concentrations 50 mmol/L EDC and 50 mmol/L 
EDC and 25 mmol/L NHS. Figure 21 shows XRD of hyaluronan fibre 
before crosslinking, and fibres crosslinked for 24 hours in solutions with concentrations 
50 mmol/L EDC and 50 EDC mmol/L and 25 mmol/L NHS. The diffraction pattern 
of pure hyaluronan fibre shows only broad peak with maximum 2-theta about 20° 
and second smaller broad peak with maximum 2-theta about 9°, corresponding 
to amorphous structures. Fibres after treatment for 1 and 24 hours with concentrations 
of 50 mmol/L EDC exhibit comparable diffraction patterns with two broad peaks 
at same angle 2-theta without any sharper peaks corresponding to crystallic structure. 
For fibres treated by 50 mmol/L EDC and 25 mmol/L NHS solution, one sharp peak 
occurs at angle 2-theta = 18.1° (corresponds to interlayer distance 4.899 Å). 
 
 
 
 
 
Figure 20 XRD of fibre before crosslinking, fibres crosslinked for 1 hour in  
solutions with concentrations of 50 mmol/L EDC and 50 mmol/L EDC with 25 mmol/L 
NHS. 
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Figure 21 XRD of fibre before crosslinking, fibres crosslinked for 24 hours in  
solutions with concentrations of 50 mmol/L EDC and 50 mmol/L EDC with 25 mmol/L 
NHS. 
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5 CONCLUSION 
The aim of presented work was to prepare stabile hyaluronan microfibers in water 
environment and optimization of the conditions. The purpose was also their 
characterization and comparison before crosslinking and after crosslinking, and between 
crosslinked fibres mutually.  
The fibre before crosslinking is stable in solution with pH 7.4 and 3 only 
for approximately 10 minutes, in solution with pH 3 for 5 minutes. The FTIR spectra 
of this sample demonstrated that new peak for esterification has occurred at 1733 cm-1.  
When fibers were crosslinked, their stability in all solutions (pH 7.4, 3, 11) has 
increased. With higher concentration of crosslinking solution and longer time 
of crosslinking, the fibres were more stable in these solutions.  
The dependence: the higher concentration of crosslinking solution and longer time 
of crosslinking, also holds for new esterification peak which appeared 
after crosslinking, approximately at 1700 cm-1. Crosslinked fibres have two peaks 
for ester bonds, first at around 1730 cm-1 for esterification after spinning (so called 
eternal esterification), and second one at around 1700 cm-1 after the crosslinking 
with crosslinking reagents. 
Thermogravimetrical analysis showed that all the tested crosslinked fibres have 
higher thermal stability than the fibre before crosslinking.  
The mechanical properties of the fibres are highly influenced by the 
heterogeneous cross-section of the fibres; therefore no dependence has occurred when 
determining these properties. 
As the best sample, was chosen the fibre crosslinked for 48 hours in the solution 
with concentration of 100 mmol/L of EDC. This fibre was stable in neutral and acidic 
solution for 48 hours and in alkali solution 15 minutes. Thermogravimetrical analysis 
determined the rate of change of the mass of this sample as 204.96 °C, which is only 
a little higher than the same value for fibre before crosslinking (204.05 °C). 
In conclusion, more types of crosslinked fibres and not crosslinked fibre were 
prepared and characterized with different techniques. Advantages of such preparation 
of fibres are its no toxicity, the fact that the procedure is a green technology because it 
is no-polluting, and there is no evaporation of the chemical agents during the process. 
Besides, it is a relatively inexpensive method thanks to the system water and sodium 
hydroxide. General conclusion is that fibres stable in water were prepared with 
the crosslinking reagents EDC and NHS. With higher concentration of crosslinking 
reagent and time of crosslinking, fibres are more stable in PBS solutions and show 
higher degree of esterification. Considering the mechanical properties, no important 
dependence was found. It is probably due to the heterogeneity the fibres, and this 
problem could be the new topic for solving in the future.   
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7 APPENDIXES 
7.1 The List of Abbreviations 
BDDE  butanediol-diglycidyl ether 
DVS  divinyl sulfone 
ECM  extracellular matrix 
EDC  1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide 
FTIR  Fourier transform infrared spectroscopy 
GAG  glycosaminoglycans 
GTA  glutaraldehyde 
HA   hyaluronic acid 
NHS  N-hydroxysuccinimide 
PBS  Phosphate buffer saline 
PEGDG  poly(ethyleneglycol) diglycidyl ether 
SEM  scanning electron microscope 
TGA  thermogravimetric analysis 
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